New Key Statistics Module, Z-Score and F-Score
NAS:FATE Key Ratios
| Market Cap $ M | 279.18 |
| Enterprise Value $ M | 201.09 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 1.77 |
| Price/Sales | 43.15 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 6.00 |
| EPS (TTM) $ | -1.05 |
| Beneish M-Score | -3.76 |
| 10-y EBITDA Growth Rate % | -6.00 |
| 5-y EBITDA Growth Rate % | 8.40 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -1.51 |
| EV-to-EBITDA | -1.65 |
| PEG | -- |
| Shares Outstanding M | 119.82 |
| Net Margin (%) | -1,941.09 |
| Operating Margin % | -2,058.08 |
| Pre-tax Margin (%) | -1,941.09 |
| Quick Ratio | 4.85 |
| Current Ratio | 4.85 |
| ROA % (ttm) | -39.89 |
| ROE % (ttm) | -60.82 |
| ROIC % (ttm) | -104.94 |
| Dividend Yield % | -- |
| Altman Z-Score | -8.01 |
FATE Number of Guru Trades
FATE Volume of Guru Trades
Gurus Latest Trades with NAS:FATE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:FATE is held by these investors
Total 2
Fate Therapeutics Inc Insider Transactions
No Available Data
News about NAS:FATE
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers